Financial Health Report: Bluebird bio Inc (BLUE)’s Ratios Tell a Tale

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

Bluebird bio Inc (NASDAQ: BLUE) closed the day trading at $1.02 up 7.03% from the previous closing price of $0.95. In other words, the price has increased by $7.03 from its previous closing price. On the day, 8.18 million shares were traded. BLUE stock price reached its highest trading level at $1.03 during the session, while it also had its lowest trading level at $0.94.

Ratios:

For a better understanding of BLUE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.

On December 08, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $3 to $7.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Obenshain Andrew sold 6,095 shares for $1.53 per share. The transaction valued at 9,311 led to the insider holds 279,998 shares of the business.

Klima Thomas J sold 4,573 shares of BLUE for $6,986 on Mar 04 ’24. The insider now owns 124,840 shares after completing the transaction at $1.53 per share. On Mar 01 ’24, another insider, Colvin Richard A, who serves as the Chief Medical Officer of the company, sold 6,770 shares for $1.53 each. As a result, the insider received 10,342 and left with 118,368 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 196596832 and an Enterprise Value of 240936928. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.05 while its Price-to-Book (P/B) ratio in mrq is 0.49. Its current Enterprise Value per Revenue stands at 11.09 whereas that against EBITDA is -1.828.

Stock Price History:

Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.88. The 50-Day Moving Average of the stock is -19.11%, while the 200-Day Moving Average is calculated to be -59.52%.

Shares Statistics:

Over the past 3-months, BLUE traded about 8.59M shares per day on average, while over the past 10 days, BLUE traded about 5875370 shares per day. A total of 192.74M shares are outstanding, with a floating share count of 189.83M. Insiders hold about 1.51% of the company’s shares, while institutions hold 61.93% stake in the company. Shares short for BLUE as of 1711584000 were 29746619 with a Short Ratio of 3.46, compared to 1709164800 on 34134876. Therefore, it implies a Short% of Shares Outstanding of 29746619 and a Short% of Float of 16.479999.

Earnings Estimates

Currently, bluebird bio, Inc. analysts are dedicated to thoroughly evaluating and rating the performance of Bluebird bio Inc (BLUE) in the stock market.The consensus estimate for the next quarter is $15.54, with high estimates of $160.67 and low estimates of $187.06.

Most Popular

[the_ad id="945"]